Pathology & Oncology Research最新文献

{"title":"Prognosis and tumor grading in bladder urothelial carcinomas with intratumoral grade heterogeneity.","authors":"Gökhan Veli Alkan, Kutsal Doğan, Meltem Türk Alkan, Evrim Önder","doi":"10.3389/pore.2026.1612553","DOIUrl":"https://doi.org/10.3389/pore.2026.1612553","url":null,"abstract":"<p><strong>Aims: </strong>Grade heterogeneity is one of the most debated issues in the grading of urothelial carcinomas. The 2022 WHO classification states that approximately one-third of urothelial carcinomas exhibit grade heterogeneity and suggests that the presence of ≥5% high-grade component may justify classification as high-grade. Nevertheless, the need for further evidence was also emphasized. This study aimed to evaluate the prognostic impact of the high-grade component in urothelial carcinomas with grade heterogeneity and to determine a threshold value for high-grade proportion that is clinically meaningful for grading.</p><p><strong>Methods: </strong>This retrospective study included 180 cases of non-muscle-invasive urothelial carcinoma with grade heterogeneity, diagnosed between January 2019 and August 2022 on TUR specimens, with available clinical data. Recurrence and survival time were assessed. Cases with >90% high-grade component were excluded.</p><p><strong>Results: </strong>Recurrence was observed in 26.7% of cases. The two-year survival rate was 73.3%. While no significant association was found between recurrence and the proportion of high-grade component, survival time significantly decreased as the proportion of high-grade component increased. ROC curve analysis identified 27.5% as the cut-off value associated with adverse prognosis.</p><p><strong>Conclusion: </strong>In non-muscle-invasive urothelial carcinomas, the proportion of high-grade component showed a strong association with survival. Together with literature findings, our results suggest that a threshold higher than 5% may be more appropriate for assigning tumors to the high-grade category. Nonetheless, risk stratification incorporating tumor size and extent remains essential for prognostic evaluation.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"32 ","pages":"1612553"},"PeriodicalIF":2.7,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13677559/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149224797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Letter to the Editor regarding the article \"gastric epithelial neoplasm of fundic-gland mucosa lineage: representative of the low atypia differentiated gastric tumour and Ki67 may help in their identification\".","authors":"Houqiang Li, Lanqing Zheng, Guodong Zhong, Linying Chen, Xin Chen","doi":"10.3389/pore.2026.1612588","DOIUrl":"https://doi.org/10.3389/pore.2026.1612588","url":null,"abstract":"","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"32 ","pages":"1612588"},"PeriodicalIF":2.7,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13662470/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149196038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of p53 status on recurrence patterns and oncologic outcomes in non-invasive high-grade endometrial cancer.","authors":"Eduardo Paulino, Thiago Branco, Guilherme Gomes de Mesquita, Andreia Cristina de Melo","doi":"10.3389/pore.2026.1612543","DOIUrl":"10.3389/pore.2026.1612543","url":null,"abstract":"<p><strong>Objective: </strong>This retrospective study evaluated the impact of p53-abnormal (p53abn) status on recurrence patterns and outcomes among patients with non-invasive, high-grade endometrial cancer (EC) treated at the Brazilian National Cancer Institute (INCA) between 2010 and 2025.</p><p><strong>Methods: </strong>Eligible patients had high-grade histologies-including endometrioid grade 3 (ECG3), serous (USC), clear cell (CC), carcinosarcoma (CS), mixed, or undifferentiated tumors-without myometrial invasion. Clinical, surgical, and pathological characteristics, as well as recurrence and survival data, were reviewed. Immunohistochemical analysis of p53 expression was performed, and p53 status was correlated with clinical outcomes, particularly recurrence rate.</p><p><strong>Results: </strong>Fifty-nine patients met the inclusion criteria, with a mean age of 65 years. Most underwent total hysterectomy with or without bilateral salpingo-oophorectomy (59.3%); 40.7% also received lymphadenectomy or omentectomy. Histologic distribution was mainly endometrioid (39.0%) and serous (39.0%). Forty-six (78%) and 13 (22%) had p53 abnormal and normal tumors. Seven patients (11.9%) received chemotherapy and 15 (25.4%) received radiotherapy. Three patients had already disease outside uterus. Among 56 patients with FIGO stage IC disease, recurrence occurred in 16.1%, predominantly at extra-pelvic sites (33.3% abdominal, 22.2% distant). Five-year recurrence was 23.2% for p53abn tumors versus 0% for wild-type, and 12.5% of patients died-mostly within the p53abn subgroup.</p><p><strong>Conclusion: </strong>The findings suggest that even in non-invasive high-grade EC, p53 abnormalities confer higher recurrence risk and poorer outcomes, while wild-type tumors show excellent prognosis. These results support individualized treatment approaches and highlight the need for larger, prospective validation studies.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"32 ","pages":"1612543"},"PeriodicalIF":2.7,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13572299/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148970660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of selected <i>ELAC2</i>, <i>MSR1</i>, <i>RNASEL</i> and <i>KLK3</i> polymorphisms with prostate cancer susceptibility in a Hungarian cohort.","authors":"Sebestyen Kovacs, Renata Szalai, Laszlo Barati, Kinga Hadzsiev","doi":"10.3389/pore.2026.1612550","DOIUrl":"10.3389/pore.2026.1612550","url":null,"abstract":"<p><strong>Background: </strong>Prostate cancer (PCa) remains a leading malignancy among men worldwide, with inherited genetic susceptibility playing a pivotal role in its pathogenesis. Although numerous single nucleotide polymorphisms (SNPs) within immune response, inflammatory, and apoptotic pathways have been linked to PCa risk, these associations often exhibit substantial inconsistency across diverse populations. This study aimed to evaluate the association of selected polymorphisms within the <i>RNASEL</i>, <i>ELAC2</i>, <i>MSR1</i>, and <i>KLK3</i> genes with PCa susceptibility in a Hungarian cohort.</p><p><strong>Methods: </strong>This case-control study included 103 histologically confirmed prostate cancer patients and 103 healthy controls recruited at the University of Pécs Department of Urology. Genotyping of selected polymorphisms was performed by PCR and Sanger sequencing at the Department of Medical Genetics. Statistical associations were evaluated using chi-square tests, odds ratios, and logistic regression.</p><p><strong>Results: </strong>A statistically nominally significant association with prostate cancer susceptibility was observed for the <i>RNASEL</i> rs486907 polymorphism, demonstrating a potential protective effect under the dominant model in the studied population (OR = 0.53, 95% CI: 0.30-0.92, p = 0.025). In the age-adjusted logistic regression analysis, this association remained statistically significant (OR = 0.56, 95% CI: 0.32-0.99, p = 0.046), suggesting that the observed effect was independent of age. In contrast, no statistically significant associations were identified between prostate cancer risk and the investigated polymorphisms in the <i>KLK3</i>, <i>MSR1</i>, or <i>ELAC2</i> genes.</p><p><strong>Conclusion: </strong>The present study demonstrated a significant association between the <i>RNASEL</i> rs486907 polymorphism and prostate cancer susceptibility in a Hungarian cohort, suggesting a potential protective effect of this variant. These findings support the possible role of inherited genetic factors in prostate cancer development and highlight the importance of population-specific genetic association studies. Further investigations involving larger cohorts are warranted to validate these observations.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"32 ","pages":"1612550"},"PeriodicalIF":2.7,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13561955/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148955198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond animal models: using human pluripotent stem cell-derived stem and progenitor cells to predict cytotoxicity in normal tissues.","authors":"Katalin Vincze, Nóra Varga, Szilárd Tóth, Anna Kamilla Kis, Rita Béres, János Miklós Réthelyi, Zoltán János Veréb, Zsuzsa Erdei, Balázs Sarkadi, Ágota Apáti","doi":"10.3389/pore.2026.1612490","DOIUrl":"10.3389/pore.2026.1612490","url":null,"abstract":"<p><strong>Background: </strong>The clinical efficacy of anticancer drugs is often limited by dose-dependent toxicity to normal cells, particularly to rapidly dividing stem and progenitor cell populations. Traditional preclinical toxicity screening relies on animal models or primary human cells/immortalized lines, both of which have significant limitations regarding scalability, reproducibility, genetic diversity, and translational relevance.</p><p><strong>Objective: </strong>This study aims to establish and validate a human pluripotent stem cell -based platform for profiling the toxicity of cytostatic drugs on healthy, dividing cell populations, and to compare their sensitivity to that of cancer cell lines.</p><p><strong>Methods: </strong>Two hiPSC lines (male and female) were reprogrammed from umbilical cord blood cells, fully characterized, and differentiated into neural progenitors and mesenchymal derivatives. Dose-response curves were generated using a dilution series of four anticancer drugs and four other pharmacologically active compounds based on cell viability. Toxic half-maximal values (IC₅₀) were determined for each cell type and compared to those obtained from conventional cancer cell lines.</p><p><strong>Results: </strong>The highest sensitivity to DNA-damaging agents was exhibited by pluripotent stem cells, followed by neural progenitors, with mesenchymal derivatives being the least sensitive. Notably, except for mesenchymal cells, both pluripotent stem cells and their differentiated derivatives were more sensitive to cytostatics than cancer cell lines.</p><p><strong>Conclusion: </strong>Human iPSC-derived stem/progenitor cells recapitulate the <i>in vivo</i> sensitivity of healthy dividing cell populations to chemotherapy. This platform offers unlimited, genetically consistent, and reproducible access to human cells, rendering it as a powerful complementary approach or even an alternative to animal models and primary human cells for early-phase drug safety profiling.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"32 ","pages":"1612490"},"PeriodicalIF":2.7,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13538076/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148888352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction: Knockdown of Sox2 inhibits OS cells invasion and migration via modulating Wnt/β-catenin signaling pathway.","authors":"","doi":"10.3389/pore.2026.1612565","DOIUrl":"https://doi.org/10.3389/pore.2026.1612565","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.1007/s12253-018-0400-1.].</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"32 ","pages":"1612565"},"PeriodicalIF":2.7,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13519594/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148841260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case Report: Pancreatic amphicrine-like carcinoma with acinar differentiation harboring a KANK4-RAF1 gene fusion.","authors":"Sabrina Kammerer, Peter Bode, Heide Schreiber, Guacimara Ortega Sanchez","doi":"10.3389/pore.2026.1612537","DOIUrl":"10.3389/pore.2026.1612537","url":null,"abstract":"<p><p>Pancreatic amphicrine-like carcinoma (ALC) is an exceptionally rare neoplasm characterized by simultaneous exocrine and endocrine differentiation within the same tumour cells. These tumours represent a diagnostic challenge because they must be distinguished from mixed neuroendocrine-non-neuroendocrine neoplasms (MiNENs), which consist of morphologically distinct tumour components. We report a case of pancreatic ALC with acinar differentiation harboring a KANK4::RAF1 fusion identified by comprehensive genomic profiling. Histologically, the tumour demonstrated acinar differentiation with expression of trypsin and BCL10 together with neuroendocrine differentiation characterized by synaptophysin and INSM1 expression within the same neoplastic population. Molecular analysis revealed a RAF1 rearrangement, a potentially actionable alteration previously described in a subset of pancreatic acinar carcinomas. The patient showed rapid disease progression despite systemic chemotherapy. Treatment with the MEK inhibitor trametinib was initiated based on the presence of a RAF1 fusion but was discontinued after 1 month because of toxicity, preventing assessment of therapeutic efficacy. This case expands the molecular spectrum of pancreatic ALC with acinar differentiation and highlights the importance of comprehensive molecular profiling in rare pancreatic neoplasms to identify potentially actionable genomic alterations.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"32 ","pages":"1612537"},"PeriodicalIF":2.7,"publicationDate":"2026-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13503299/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148819259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SPOCK1 overexpression suggests poor prognosis in head and neck squamous cell carcinomas.","authors":"Noemi Piroska Jakob, Matyas Majoros, Imre Uri, Helga Szakadati, Ede Birtalan, Kornelia Baghy, Zoltan Kelemen, Laszlo Tamas, Kornel Danos, Tibor Krenacs","doi":"10.3389/pore.2026.1612448","DOIUrl":"10.3389/pore.2026.1612448","url":null,"abstract":"<p><p>Head and neck squamous cell carcinomas (HNSCCs) are mostly associated with smoking, alcohol intake, and/or human papillomavirus HPV16 and/or HPV18 infection. However, most tumors are diagnosed at an advanced stage. In the search for biomarkers of HNSCC, we studied the prognostic role of SPOCK1, a heparan sulfate proteoglycan. In HNSCC, SPOCK1 expression was tested both at <i>in silico</i> mRNA level using the Kaplan-Meier Plotter and at <i>in situ</i> protein level after SPOCK1 immunohistochemistry after whole slide digitalization. Protein expression results were analyzed using H-Scores, both by eye-control testing and with a machine-learning-based automated image analysis tool, DensitoQuant. SPOCK1 mRNA expression was found to be significantly higher in oral carcinomas than in the normal oral mucosa (log-rank p = 5.76e-06). Elevated SPOCK1 mRNA expression was consistently associated with a strongly reduced overall survival (OS; HR = 1.57 (1.2-2.06); log-rank p = 0.001) in HNSCC. This was particularly true for tumors with high (log-rank p = 0.00085) vs. low (log-rank p = 0.55) neoantigen (NeoAG) levels, at median antigen level stratification. Both the Cox-regression analysis and the log-rank test revealed elevated SPOCK1 protein levels in association with significantly reduced OS in our 97 HNSCC patients (both p = 0.002), which was supported by automated image analysis testing (p = 0.008 and p = 0.044, respectively). Our findings suggest that SPOCK1 can be a candidate adverse prognostic biomarker also in HNSCC. Therefore, SPOCK1 overexpression may specify a group of oral cancers with aggressive tumor biology.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"32 ","pages":"1612448"},"PeriodicalIF":2.7,"publicationDate":"2026-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13494527/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148796611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular classification of endometrial carcinoma: clinical utility of an NGS panel with targeted detection of 116 cancer-related genes.","authors":"Lingfeng Chen, Zhijie You, Xunbin Yu, Yijuan Wu, Xin Chen, Jie Lin","doi":"10.3389/pore.2026.1612465","DOIUrl":"10.3389/pore.2026.1612465","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to evaluate the efficacy of a single-test, targeted DNA next-generation sequencing (NGS) panel in classifying endometrial carcinoma (EC) into molecular subtypes and to compare its performance with that of the established Sanger sequencing + immunohistochemistry (Sanger + IHC) molecular classification.</p><p><strong>Methods: </strong>Targeted DNA NGS was performed on 131 samples using the clinically validated AmoyDx® Comprehensive Panel, and a commercially available targeted AmoyDx EC Panel covering POLE, TP53, and MSI was used for 63 samples.</p><p><strong>Results: </strong>The concordance between the NGS and Sanger + IHC classifications was 93.8% (182/194 cases), with a kappa value of 0.908. The exclusion of seven discordant <i>POLE</i> mutations improved concordance to 97.4% (kappa = 0.962). NGS identified 30 <i>POLE</i> mutations compared to 23 detected by Sanger sequencing, which missed low-frequency variants. Microsatellite instability (MSI) analysis and mismatch repair (MMR) immunohistochemistry (IHC) results were highly concordant (97.9%). However, NGS-based <i>TP53</i> mutation detection showed moderate agreement with the p53 IHC results (kappa = 0.688). Mutations associated with targeted therapy trials, including PTEN (76.3%), PIK3CA (50.4%), and ARID1A (35.9%), were found in 131 EC samples.</p><p><strong>Conclusion: </strong>These findings indicate that NGS-based molecular classification aligns well with Sanger + IHC molecular classification and offers higher sensitivity than Sanger sequencing, thereby improving the identification of mutations associated with targeted therapy trials. This enhances the prognosis and treatment planning for patients with advanced EC.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"32 ","pages":"1612465"},"PeriodicalIF":2.7,"publicationDate":"2026-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13457160/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148713079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TRK immunohistochemistry in pediatric rhabdomyosarcomas: diagnostic and prognostic utility and limitations.","authors":"Renáta Lajti, Katalin Dezső, Zoltán Sápi, Gergő Papp, Anna Mohás, Bence Bukovszky, Sándor Szabó, Luca Felkai, Monika Csóka","doi":"10.3389/pore.2026.1612374","DOIUrl":"10.3389/pore.2026.1612374","url":null,"abstract":"<p><p>Rhabdomyosarcoma is the third most common extracranial solid tumor in childhood. Treatment of patients is multimodal, based on systemic chemotherapy and local therapy by surgery and/or radiotherapy. Although standard therapies result in an overall survival of more than 75% for patients in the low-risk group, the prognosis for high-risk patients remains poor. For this reason, new therapeutic alternatives are needed. One such option is the use of specific Tropomyosin receptor kinase (TRK) inhibitors, which provides the opportunity of targeted therapeutic treatment for patients carrying <i>Neurotrophic Receptor Tyrosine Kinase</i> (<i>NTRK</i>) translocations. As the frequency of these aberrations is not yet known in rhabdomyosarcomas, the aim of this study was to map the pan-TRK expression profile of rhabdomyosarcomas by an affordable method and to investigate the link between the expression and the clinicopathological features. We studied samples of patients diagnosed with rhabdomyosarcoma at the Pediatric Center, Semmelweis University, Budapest, Hungary. Using immunohistochemistry, we found that pan-TRK expression was detected in 38% of the cases studied. The expression was present in a significantly higher proportion of samples in the unfavorable, alveolar histological subtype. However, no <i>NTRK</i> fusion was detected in the 17 TRK expressing samples.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"32 ","pages":"1612374"},"PeriodicalIF":2.7,"publicationDate":"2026-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13423737/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148654125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}